Q1 26 EPS
$1.15
BEAT +0.33%
Est. $1.15
Q1 26 Revenue
$11.16B
BEAT +1.51%
Est. $11.00B
vs S&P Since Q1 26
-8.5%
TRAILING MARKET
ABT -1.9% vs S&P +6.6%
Market Reaction
Did ABT Beat Earnings? Q1 2026 Results
Abbott Laboratories kicked off 2026 with a solid beat on both top and bottom lines, extending its streak of beating consensus EPS estimates to four consecutive quarters. The healthcare giant posted adjusted EPS of $1.15 for Q1 2026, edging past the $… Read more Abbott Laboratories kicked off 2026 with a solid beat on both top and bottom lines, extending its streak of beating consensus EPS estimates to four consecutive quarters. The healthcare giant posted adjusted EPS of $1.15 for Q1 2026, edging past the $1.15 consensus estimate by 0.33%, while revenue climbed 7.8% year over year to $11.16 billion, ahead of the $11.00 billion Wall Street had anticipated. The quarter's defining event was the March completion of Abbott's $21 billion acquisition of Exact Sciences, which immediately added a new Cancer Diagnostics business to its portfolio and contributed $96 million in revenue from partial-quarter Cologuard and Cancerguard sales, a move that investors and analysts have been closely watching for its long-term impact on Abbott's diagnostics franchise. Medical Devices remained the engine of organic momentum, reaching $5.54 billion with continuous glucose monitor sales alone hitting $2.08 billion, as Abbott faces intensifying competition in that space. Looking ahead, the company projects full-year 2026 adjusted EPS of $5.38 to $5.58 and comparable sales growth of 6.5% to 7.5%, even as Exact Sciences integration absorbs roughly $0.20 of dilution.
Key Takeaways
- • Medical Devices led by double-digit growth in Electrophysiology, Heart Failure, and Rhythm Management
- • Continuous glucose monitor sales grew 14.2% on a reported basis
- • Established Pharmaceuticals driven by double-digit growth in several Latin America and Asia Pacific emerging markets
- • Core Laboratory Diagnostics growth driven by U.S., Europe, and Latin America
- • Cancer Diagnostics driven by double-digit Cologuard growth and Cancerguard sales
ABT YoY Financials
Q1 2026 vs Q1 2025, source: SEC Filings
ABT Revenue by Segment
With YoY comparisons, source: SEC Filings
ABT Revenue by Geography
With YoY comparisons, source: SEC Filings
“Our first-quarter results were aligned with our expectations to start the year. The acquisition of Exact Sciences adds another high-growth business to the Abbott portfolio, further strengthening our confidence in delivering accelerating growth as we move through the year.”
— Robert B. Ford, Q1 2026 Earnings Press Release
ABT Earnings Trends
ABT vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
ABT EPS Trend
Earnings per share: estimate vs actual
ABT Revenue Trend
Quarterly revenue: estimate vs actual
ABT Quarterly Results
6 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q2 26 BEAT | $1.28 | $1.31 | +2.63% | $12.59B | +0.62% |
| Q1 26 BEAT | $1.15 | $1.15 | +0.33% | $11.16B | +1.51% |
| Q4 25 BEAT FY | $1.49 | $1.50 | +0.34% | $11.46B | -2.91% |
| FY Full Year | $5.17 | $5.15 | -0.42% | $44.33B | -0.78% |
| Q3 25 BEAT | $1.30 | $1.30 | +0.05% | $11.37B | -0.21% |
| Q2 25 BEAT | $1.25 | $1.26 | +0.80% | $11.14B | +1.08% |
| Q1 25 BEAT | $1.07 | $1.09 | +1.75% | $10.36B | -0.57% |